Vasculitis Treatment Market - Forecast(2024 - 2030)

Report Code: HCR 26898 Report Format: PDF + Excel

Vasculitis Treatment Market Overview

The Vasculitis Treatment Market size is estimated to reach $621 million by 2027. Furthermore, it is poised to grow at a CAGR of 5.9% over the forecast period of 2022-2027. Vasculitis is a blood vessel inflammation disease, in which the blood vessels thicken thereby reducing the width and passageway for the blood to pass through. Moreover, if the blood flow gets restricted, organ or tissue damage is bound to happen. Vasculitis is more often than not very rare and can potentially affect one or more organs. Large vessel vasculitis and small & medium vessel vasculitis are some of the predominant conditions found in the said condition. The latter form of vasculitis is also known as Cutaneous vasculitis. Another form of vessel thickening condition is known as Wegener’s granulomatosis, which can predictively affect ears, nose, throat, lungs, and kidneys. Antineutrophil Cytoplasmic Antibodies testing is usually performed to diagnose the said condition. The diagnosis forms the first half of treatment of vasculitis, and blood tests, imaging tests, biopsy, and angiography can form the crucial support of diagnosis basis. The treatment options remain limited. For one to continue on medications, immunosuppressants and corticosteroids are given. However, if vasculitis worsens it can cause an aneurysm, thereby, needing surgical intervention. The increasing prevalence of chronic diseases with the increase in cases of peripheral arterial disease have been the key factors driving the Vasculitis Treatment Industry forward in the forecast period.

Report Coverage

The report: “Vasculitis Treatment Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Vasculitis Treatment Market.

By Disease Type- Small and Medium Vessel Vasculitis and Large Vessel Vasculitis.
By Diagnosis- Blood Tests, Imaging Tests, Angiography, and Biopsy.
By Treatment Type- Medications and Surgery.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America’s vasculitis treatment market held a dominant market share in the year 2021. It is owing to rising awareness pertaining to such diseases, and the medical literacy which has allowed the population to readily find treatment for such conditions. However, Asia-Pacific is set to offer lucrative growth opportunities owing to the enhanced focus of various governments for their medical infrastructure.
  • The rise in the geriatric population along with the prevalence of chronic diseases which are fuelled by sedentary lifestyles are the major driver for the market. However, medication implications and the lack of awareness regarding such prospects in developing countries are hampering the market growth.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Vasculitis Treatment Market Report.

    Vasculitis Treatment Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

Vasculitis Treatment Market Segmentation Analysis - By Treatment Type

The Vasculitis treatment market based on treatment type can be further segmented into medications and surgeries. Medication’s segment held a dominant market share in the year 2021. It is owing to the wide range of medications now being used in the treatment of such conditions. Corticosteroids are the predominant treatment course, and they have the potential to exhibit faster effects than any other medication. In various studies, around 78-80% of participants have had positive effects or an immediate benefit on the patients.

Moreover, the medication segment is estimated to be the fastest-growing, with a CAGR of 6.6% over the forecast period of 2022-2027. It is owing to the recent advances being made in the field of biologics. Rituximab, infliximab, and Adalimumab are gaining immense market traction owing to low levels of toxicity and no apparent side effects in long term, as compared to the other medication treatment lines.

Vasculitis Treatment Market Segmentation Analysis - By Disease Type

The Vasculitis treatment market based on disease type can be further segmented into Small Vessel Vasculitis, Middle Vessel Vasculitis, and Large Vessel Vasculitis. The large vessel Vasculitis held a dominant market share in the year 2021. It is highly prevalent in people older than 50, and the most common symptom for the same starts with flu-like symptoms, fatigue, and fever. Moreover, Takayasu’s arteritis another type of vasculitis is rare and affects two to three people out of a million. Further, giant cell arteritis incidence is close to 1/5,000-1/17,000 for adults aged over 50.

Moreover, the large cell vasculitis segment is estimated to be the fastest-growing, with a CAGR of 6.8% over the forecast period of 2022-2027. It is owing to the rising geriatric population, which is taking a grip on a global level. Furthermore, CDC predicts, that by 2040, the population composition will have 21% as senior population. With the growing numbers of the senior population, the large vessel vasculitis is supposed to grow at a steadfast pace.

Vasculitis Treatment Market Segmentation Analysis - By Geography

The Vasculitis Treatment Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s vasculitis treatment market held a dominant market share of 34% as compared to the other regions in the year 2021. It is associated with higher levels of medical literacy rates, and the prevalence of such diseases in the state. Moreover, countries such as the US spends extensively on their population for better medical treatment, which has further helped the market. As per the latest figures, the country spends close to $11,582/person for its medical treatment and expenditure. Further, favorable reimbursement healthcare policies make it easier for diagnostics.

However, Asia-Pacific is set to offer lucrative growth opportunities to marketers in the projected period of 2022-2027. It is owing to significant medical development across the regions. Secondly, manufacturers are outsourcing the treatment processes to the CROs, which has further paced the journey for finding better treatment alternatives. Owing to such factors, the market is expected to grow at a steadfast pace.

Vasculitis Treatment Market Drivers

The likelihood of developing vasculitis near silica extraction sites has been a key environmental factor

Vasculitis has often been termed as a genetically transferred condition, however, recent studies have thrown light on how vasculitis cases have been found near the excavation sites of silica. Silica has been commonly found in nature as quartz. Moreover, quarries, where rocks, sands, and minerals are extracted, are prone to have silica exposure. A case study, which took place in Alsace, France which was close to quarries had more cases of vasculitis. 185 cases were identified within that region who had vasculitis, of which 120 had granulomatosis with polyangiitis, 35 had microscopic polyangiitis (MPA), and 30 with renal limited vasculitis. Lastly, researchers went on to decipher that the risk of developing AAV was 2.5x higher in communities that had quarries, of which the risk was 3.2x more for GPA, while it was 3.1x higher for RPA. Furthermore, owing to the recent climate change amendments, more and more sites are excavated for minerals, as they are the popular alternatives for fuel and green energy. Treatments are directly correlated with more diseases being incurred. Hence, the vasculitis treatment industry outlook looks evenly poised in the projected period of 2022-2027.

Increasing health literacy has positively aided the vasculitis treatment market

Health Literacy is the degree through which individuals can obtain and understand processes, basic health information, treatment needs, and understanding vital information which will improve their health decisions. Additionally, Medicare beneficiaries in counties with the highest health literacy levels experience better outcomes than those living in counties with the lowest health literacy levels, including 31% more flu shots, 26% fewer avoidable hospitalizations, 18% fewer emergency department visits, 13% lower costs per beneficiary, 9% fewer hospital readmissions. With the overall increment in health literacy, the Vasculitis treatment market has positively benefitted.

Vasculitis Treatment Market Challenges

The medical implication of drugs to treat Vasculitis has hampered market growth

Corticosteroids have had a long history of causing side effects to the patients. Glucocorticoids induced osteoporosis has been the most prevalent and devasting effect. Moreover, 40% of the patients on long-term steroidal usage can develop bone loss which can further cause fractures. Systemic glucocorticoids cause a dose-dependent increase in fasting glucose levels and a more significant increase in postprandial values in patients without pre-existing diabetes mellitus, but the development of de novo diabetes in a patient with initially normal glucose tolerance is uncommon. Lastly, cardiovascular adverse effects, dermatologic adverse effects, and ophthalmologic adverse effects are some of the predominant implications of the drugs being used as a treatment method.

Vasculitis Treatment Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Vasculitis Treatment Market. Vasculitis Treatment top 10 companies include:

  1. Celgene Corporation,
  2. Merck & Co,
  3. Novartis AG,
  4. F. Hoffmann-La Roche,
  5. GlaxoSmithKline plc,
  6. Bristol-Myers Squibb Company,
  7. RNL BIO Co., Ltd.,
  8. Teijin Pharma Limited,
  9. Anthera Pharmaceuticals‚ Inc.,
  10. Human Genome Sciences, Inc.

Recent Developments

  • In May 2021, Avacopan has been recognized as the substitute for corticosteroids in the treatment for ANCA-associated vasculitis. The immunosuppressive drug is equivalent to the latter in terms of effectiveness. It utilizes and complements the C5a receptor inhibitor. The results governed that after 26 weeks of treatment, the drug was able to maintain its effect. Moreover, there was a significant reduction in the cases of toxicity.
  • In September 2020, Exagen launched a test-to-aid in the detection of ANCA-associated Vasculitis. In the product portfolio of Exagen, autoimmune diagnosis and detection have been the key feature. The new product- AVISE Vasculitis AAV, the testing panel of individual analytes will help physicians with rapid results. AVISE Vasculitis AAV enhances Exagen’s catalog of AVISE® tests, allowing physicians further access to Exagen’s specialty lab dedicated to autoimmune diseases.
  • In January 2019, treatment of ANCA Vasculitis with Rituximab has been gaining traction. Firstly, it avoids the typical side effects of corticosteroids. Moreover, the treatment promoted itself, as it shows no inferiority in terms of cyclophosphamide. However, the drug might take a month or two to cater to its full effect, hence, researchers believe if the condition is to be controlled faster, steroidal treatment should opt. However, for the other, it is excellent induction therapy.

Relevant Titles

Report Code- HCR 0958

Report Code- HCR 22428

For more Lifesciences and Healthcare related reports, please click here

1. Vasculitis Treatment Market Overview
    1.1 Definitions and Scope
2. Vasculitis Treatment Market- Executive Summary
3. Vasculitis Treatment Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis 
4. Vasculitis Treatment Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Vasculitis Treatment Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Vasculitis Treatment Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Vasculitis Treatment Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Vasculitis Treatment Market- By Disease Type (Market Size –$Million/$Billion) 
    8.1 Small Vessel Vasculitis
        8.1.1 Wegener’s Granulomatosis
        8.1.2 Microscopic polyangiitis 
        8.1.3 Churg Strauss Syndrome
        8.1.4 Others
    8.2 Medium Vessel Vasculitis
        8.2.1 Kawasaki Disease
        8.2.2 Polyarteritis Disease
    8.3 Large Vessel Vasculitis
        8.3.1 Giant Cell Arteritis
        8.3.2 Takayasu’s Arteritis
        8.3.3 Aortitis
9. Vasculitis Treatment Market- By Diagnosis (Market Size –$Million/$Billion) 
    9.1 Blood Tests
    9.2 Imaging Tests
    9.3 Angiography
    9.4 Biopsy
    9.5 Others
10. Vasculitis Treatment Market- By Treatment Type (Market Size –$Million/$Billion) 
    10.1 Medication
    10.1 Corticosteroids
    10.2 Immunosuppressants
    10.3 Biologics
    10.2 Surgery
11. Vasculitis Treatment Market - By Geography (Market Size -$Million/Billion)
    11.1 North America
        11.1.1 U.S
        11.1.2 Canada
        11.1.3 Mexico
    11.2 South America
        11.2.1 Brazil
        11.2.2 Argentina
        11.2.3 Chile
        11.2.4 Colombia
        11.2.5 Rest of South America
    11.3 Europe
        11.3.1 Germany
        11.3.2 France
        11.3.3 UK
        11.3.4 Italy
        11.3.5 Spain
        11.3.6 Russia
        11.3.7 Rest of Europe
    11.4 Asia-Pacific
        11.4.1 China
        11.4.2 Japan
        11.4.3 South Korea
        11.4.4 India
        11.4.5 Australia & New Zealand
        11.4.6 Rest of APAC
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Vasculitis Treatment Market - Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs, and partnerships
13. Vasculitis Treatment Market – Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key Companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Vasculitis Treatment Market – Key Company List by Country Premium (Premium)
15. Vasculitis Treatment Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies

LIST OF TABLES

1.Global Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
1.1 Corticosteroid Market 2023-2030 ($M) - Global Industry Research
1.2 Immunosuppressant Market 2023-2030 ($M) - Global Industry Research
1.3 Biologics Market 2023-2030 ($M) - Global Industry Research
2.Global Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
2.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Global Industry Research
2.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Global Industry Research
3.Global Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
3.1 Govenrment Market 2023-2030 ($M) - Global Industry Research
3.2 Hospital Market 2023-2030 ($M) - Global Industry Research
3.3 Medical Clinic Market 2023-2030 ($M) - Global Industry Research
4.Global Vasculitis Treatment Market, By Drug Class Market 2023-2030 (Volume/Units)
4.1 Corticosteroid Market 2023-2030 (Volume/Units) - Global Industry Research
4.2 Immunosuppressant Market 2023-2030 (Volume/Units) - Global Industry Research
4.3 Biologics Market 2023-2030 (Volume/Units) - Global Industry Research
5.Global Vasculitis Treatment Market, By Disease Type Market 2023-2030 (Volume/Units)
5.1 Small Vessel Vasculitis Market 2023-2030 (Volume/Units) - Global Industry Research
5.2 Medium Vessel Vasculitis Market 2023-2030 (Volume/Units) - Global Industry Research
6.Global Vasculitis Treatment Market, By End User Market 2023-2030 (Volume/Units)
6.1 Govenrment Market 2023-2030 (Volume/Units) - Global Industry Research
6.2 Hospital Market 2023-2030 (Volume/Units) - Global Industry Research
6.3 Medical Clinic Market 2023-2030 (Volume/Units) - Global Industry Research
7.North America Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
7.1 Corticosteroid Market 2023-2030 ($M) - Regional Industry Research
7.2 Immunosuppressant Market 2023-2030 ($M) - Regional Industry Research
7.3 Biologics Market 2023-2030 ($M) - Regional Industry Research
8.North America Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
8.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
8.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
9.North America Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
9.1 Govenrment Market 2023-2030 ($M) - Regional Industry Research
9.2 Hospital Market 2023-2030 ($M) - Regional Industry Research
9.3 Medical Clinic Market 2023-2030 ($M) - Regional Industry Research
10.South America Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
10.1 Corticosteroid Market 2023-2030 ($M) - Regional Industry Research
10.2 Immunosuppressant Market 2023-2030 ($M) - Regional Industry Research
10.3 Biologics Market 2023-2030 ($M) - Regional Industry Research
11.South America Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
11.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
11.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
12.South America Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
12.1 Govenrment Market 2023-2030 ($M) - Regional Industry Research
12.2 Hospital Market 2023-2030 ($M) - Regional Industry Research
12.3 Medical Clinic Market 2023-2030 ($M) - Regional Industry Research
13.Europe Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
13.1 Corticosteroid Market 2023-2030 ($M) - Regional Industry Research
13.2 Immunosuppressant Market 2023-2030 ($M) - Regional Industry Research
13.3 Biologics Market 2023-2030 ($M) - Regional Industry Research
14.Europe Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
14.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
14.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
15.Europe Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
15.1 Govenrment Market 2023-2030 ($M) - Regional Industry Research
15.2 Hospital Market 2023-2030 ($M) - Regional Industry Research
15.3 Medical Clinic Market 2023-2030 ($M) - Regional Industry Research
16.APAC Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
16.1 Corticosteroid Market 2023-2030 ($M) - Regional Industry Research
16.2 Immunosuppressant Market 2023-2030 ($M) - Regional Industry Research
16.3 Biologics Market 2023-2030 ($M) - Regional Industry Research
17.APAC Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
17.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
17.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
18.APAC Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
18.1 Govenrment Market 2023-2030 ($M) - Regional Industry Research
18.2 Hospital Market 2023-2030 ($M) - Regional Industry Research
18.3 Medical Clinic Market 2023-2030 ($M) - Regional Industry Research
19.MENA Vasculitis Treatment Market, By Drug Class Market 2023-2030 ($M)
19.1 Corticosteroid Market 2023-2030 ($M) - Regional Industry Research
19.2 Immunosuppressant Market 2023-2030 ($M) - Regional Industry Research
19.3 Biologics Market 2023-2030 ($M) - Regional Industry Research
20.MENA Vasculitis Treatment Market, By Disease Type Market 2023-2030 ($M)
20.1 Small Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
20.2 Medium Vessel Vasculitis Market 2023-2030 ($M) - Regional Industry Research
21.MENA Vasculitis Treatment Market, By End User Market 2023-2030 ($M)
21.1 Govenrment Market 2023-2030 ($M) - Regional Industry Research
21.2 Hospital Market 2023-2030 ($M) - Regional Industry Research
21.3 Medical Clinic Market 2023-2030 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Vasculitis Treatment Market Revenue, 2023-2030 ($M)
2.Canada Vasculitis Treatment Market Revenue, 2023-2030 ($M)
3.Mexico Vasculitis Treatment Market Revenue, 2023-2030 ($M)
4.Brazil Vasculitis Treatment Market Revenue, 2023-2030 ($M)
5.Argentina Vasculitis Treatment Market Revenue, 2023-2030 ($M)
6.Peru Vasculitis Treatment Market Revenue, 2023-2030 ($M)
7.Colombia Vasculitis Treatment Market Revenue, 2023-2030 ($M)
8.Chile Vasculitis Treatment Market Revenue, 2023-2030 ($M)
9.Rest of South America Vasculitis Treatment Market Revenue, 2023-2030 ($M)
10.UK Vasculitis Treatment Market Revenue, 2023-2030 ($M)
11.Germany Vasculitis Treatment Market Revenue, 2023-2030 ($M)
12.France Vasculitis Treatment Market Revenue, 2023-2030 ($M)
13.Italy Vasculitis Treatment Market Revenue, 2023-2030 ($M)
14.Spain Vasculitis Treatment Market Revenue, 2023-2030 ($M)
15.Rest of Europe Vasculitis Treatment Market Revenue, 2023-2030 ($M)
16.China Vasculitis Treatment Market Revenue, 2023-2030 ($M)
17.India Vasculitis Treatment Market Revenue, 2023-2030 ($M)
18.Japan Vasculitis Treatment Market Revenue, 2023-2030 ($M)
19.South Korea Vasculitis Treatment Market Revenue, 2023-2030 ($M)
20.South Africa Vasculitis Treatment Market Revenue, 2023-2030 ($M)
21.North America Vasculitis Treatment By Application
22.South America Vasculitis Treatment By Application
23.Europe Vasculitis Treatment By Application
24.APAC Vasculitis Treatment By Application
25.MENA Vasculitis Treatment By Application
26.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.F. Hoffmann-La Roche Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Celgene Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Novartis Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Gilead, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Bristol-Myers Squibb Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Novo Nordisk A/S, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Eli Lilly And Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Ablynx, Sales /Revenue, 2015-2018 ($Mn/$Bn)